Clinical Trial Update: A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating the combination of Datopotamab Deruxtecan, carboplatin, and pembrolizumab for treatment-naive brain metastases from non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Datopotamab Deruxtecan (Dato-DXd) (datopotamab deruxtecan)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Latin American Cooperative Oncology Group | Conditions: Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING